The median OS for WT NSCLC patients was 18.5 months (95% CI: 13.7 to 23.2 months) and 26.0 months (95% CI: 19.4 to 32.5 months) for the BRAF mutated NSCLC patients. This evidence concerns the gene BRAF and non-small cell lung carcinoma.